Drugs / LC106
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07305844 | Apr → Jun 2026 overdue | bacterial vaginosis | Caroline Mitchell | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06135974 | Feb → Dec 2024 | bacterial vaginosis | Massachusetts General Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LC106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07305844 ↗ |
| Modality | Other / unclassified | “multi-strain vaginal L. crispatus live biotherapeutic product (LBP)” NCT06135974 ↗ |
| Route | Other | “receive 7 days of vaginal study product” NCT06135974 ↗ |